Obesity and High Genetic Vulnerability cause Diabetes in India

IMARC Group, one of the world’s leading research and advisory firms, finds that the total number of diabetes patients in India grew at CAGR of nearly 3% during 2004 - 2012. Estimates from their latest report entitled “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti-diabetics, Insulin and Diagnostics”, suggests that the total number of diabetes patients in India is expected to reach 107 million by 2032.

Findings from the report suggest that a major driver of the diabetes epidemic in India is the increasing levels of obesity. The Indian population that had faced under nutrition for a long time is now exposed to high fat diets and sedentary lifestyles. As a result of increasing disposable incomes and flourishing fast food chains, there were around 157 million overweight and 24 million obese people living in India in 2010. The report expects these levels to increase significantly by 2015.

Apart from the increasing obesity levels, the report also found that Indians are genetically more vulnerable to diabetes compared to other population groups. According to an analyst at IMARC Group “As a result of a higher percentage of body fat to muscle, Indians are more vulnerable to type-2 diabetes compared to other population groups. This fat increases the sugar levels as it gets deposited around the abdomen and interferes with insulin. As a result, Indians get diabetes at a much younger age compared to other population groups”.

IMARC’s new report “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti-diabetics, Insulin and Diagnostics” provides an analytical and statistical insight into the Indian diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in India. The report has segmented the Indian diabetes market into three segments - Oral Anti-diabetics, Insulin and Diabetes Diagnostics. For each of the aforementioned categories, the report provides historical and future market sales, performance of key classes and the performance of top players.

The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Indian diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Indian diabetes market in some form or the other.

Wockhardt Launches New Insulin Glaritus in India

Pharmaceutical and biotechnology major Wockhardt has announced the launch of its new insulin (Glaritus), a recombinant long acting human insulin analogue. Wockhardt is only the 1st company in the world after the innovator to launch this new insulin (Glaritus) that works slowly for over 24 hours. Currently, the worldwide market for this insulin (Glargine) is $2 billion. As per ORG IMS, the current market for analogues in India is Rs. 120 crores growing at 37% per annum. This new insulin (Glaritus) has been successfully clinically tested on 300 diabetic patients for safety & efficacy parameters and is approved by the Drug Controller General of India.

“Back in 2003, when I promised that we would launch Glaritus, the world’s most advanced insulin, there was disbelief all around. Today, the world will look at India in admiration. The nation’s biotechnology prowess would once again be a global talking point,” said Wockhardt Chairman Habil Khorakiwala. “Wockhardt becomes the first company in the biotechnology space to move from simple biologicals to complex biologicals with vast experience in both, E.coli and Yeast platforms,” he further added.

The launch of Glaritus is a significant landmark for India, which has one of the highest diabetes affected populations in the world. The advantage of Glaritus is that it is a once daily dose and provides basal glucose control over 24 hours. Glaritus can hence be easily combined with other oral medications of diabetes for effective blood glucose control. Moreover, Glaritus is meal independent, peakless insulin, which reduces incidences of hypoglycemia significantly. All this translates into more compliance to insulin therapy, improved blood glucose control and therefore slower progression of diabetes related complications.

Glaritus is available to the patients as reusable and disposable pen delivery devices. Wockhardt is one of the few select companies in the world to patent the technology of pen based insulin delivery devices, which is one of the most preferred modes of insulin injection across the globe today. Wockhardt insulin pen devices are ISO 11608 approved and have won the IndiaStar, AsiaStar and the WorldStar awards for excellence in packaging technology for 2008. Glaritus is manufactured at Wockhardt’s state-of-the-art biotech park in Aurangabad.

Wockhardt, over the recent years has built a comprehensive diabetes management portfolio that includes insulins, oral medications, blood glucose monitors & diabetes nutrition products.

Source: newsgaze.com

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 15 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, MHRA or other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API’s, the dosage forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including the USA, UK, Ireland, France, and Germany with a multi-ethnic workforce from 14 different nationalities.